Benralizumab (Fasenra)

Provider Order Form rev. 10/12/2022



	Referral Status:	New Referral	□ Updated Orde	r 🛛 Order Renewal	
me:		DOB:			
ICD-10 descr	iption:				
		We	ight (lbs/kg):	Height:	
□ Continuing Therapy	Last Treatme	Last Treatment Date: Next Due Date:			
	Referral Coor	Referral Coordinator Email:			
	Provider NPI:	Provider NPI:			
	Phone:		Fax:		
	City:		State: Zip	Code:	
	THERAPY A	DMINISTRATIO	N		
sing Procedures, including procedure observation	● Dos ● Rou ● Fre wee □ Patient i □ Refills: [Dose: Ø 30mg Route: Ø subcutaneous injection Frequency: □ every 4 weeks for 3 doses followed by every 8 weeks / □ every 8 weeks □ Patient is required to stay for 30-minute observation 			
	ICD-10 descr	me: ICD-10 description: Continuing Therapy Last Treatme Referral Coor Provider NPI: Phone: City: THERAPY A sing Procedures, including procedure observation I Ber Oos Rou Fre wea Patient i Refills: D	me: ICD-10 description: We Continuing Therapy Last Treatment Date: Continuing Therapy Last Treatment Date: Referral Coordinator Email: Provider NPI: Phone: City: THERAPY ADMINISTRATIO Benralizumab (Fasen Dose: 🖾 30mg Route: 🖾 subcutaneo Frequency: 🗌 every 4 weeks / 🗌 every 8 we Refills: 🗆 Zero / 🗌 for 12 n	me: DOB: ICD-10 description: COntinuing Therapy Last Treatment Date: Next Due I Continuing Therapy Last Treatment Date: Next Due I Referral Coordinator Email: Provider NPI: Phone: Fax: City: State: Zip THERAPY ADMINISTRATION Sing Procedures, including Procedure observation I Benralizumab (Fasenra) Dose: I 30mg Route: I subcutaneous injection Frequency: I every 4 weeks for 3 doses f weeks / I every 8 weeks Patient is required to stay for 30-minute obse Refills: I Zero / I for 12 months / I	

*Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions.

Provider Name (Print)

Provider Signature

Date

Please include the following information when submitting a referral for Fasenra:

*List of current medications treating disease

*Lab results showing eosinophil count

*Clinicals showing number of asthma exacerbations in the last 12 months

*Clinicals showing that the patient has severe asthma and has an eosinophilic phenotype *FEV1 test results